炎症可能是胰岛素抵抗与精神分裂症的共同机制:双向两样本孟德尔随机化研究
研究利用大规模全基因组关联研究汇总数据进行双向两样本孟德尔随机化分析,未发现心血管代谢特征与精神分裂症之间存在显著因果关联;但遗传预测的炎症相关胰岛素抵抗表型(空腹胰岛素升高、高密度脂蛋白降低)与精神分裂症相关,校正C反应蛋白后关联消失,提示炎症可能是共同原因。
要点
- 未发现心血管代谢特征与精神分裂症之间的显著因果关联。
- 遗传预测的空腹胰岛素升高与精神分裂症风险增加相关(OR=2.95)。
- 校正C反应蛋白后关联消失,提示炎症可能是共同机制。
核心结论
- 研究支持炎症是胰岛素抵抗和精神分裂症的共同原因,可能部分解释两者临床共病现象。
- 炎症和免疫通路可能成为预防或治疗精神分裂症及共病胰岛素抵抗的新靶点。
研究设计与样本
- 采用双向两样本单变量和多变量孟德尔随机化分析,数据来自多个大规模全基因组关联研究联盟的欧洲成人汇总数据。
- 暴露数据来源包括MAGIC(最多108,557人)、DIAGRAM(最多435,387人)、GLGC(最多173,082人)、GIANT(最多339,224人)、PGC(最多105,318人)和CHARGE(最多204,402人)。
主要发现
- 遗传预测的空腹胰岛素升高与精神分裂症相关(Wald ratio OR=2.95,95%CI 1.38-6.34,Holm-Bonferroni校正P=0.035)。
- 遗传预测的高密度脂蛋白降低与精神分裂症相关(Wald ratio OR=0.55,95%CI 0.36-0.84,P=0.035)。
- 校正C反应蛋白后,空腹胰岛素与精神分裂症的关联衰减至无效(Wald ratio OR=1.02,95%CI 0.37-2.78,P=0.975)。
- 校正C反应蛋白后,高密度脂蛋白与精神分裂症的关联衰减至无效(Wald ratio OR=1.00,95%CI 0.85-1.16,P=0.849)。
临床怎么用
- 在精神分裂症患者中关注胰岛素抵抗和炎症标志物,可能有助于识别共病风险。
- 针对炎症通路的干预可能同时改善精神分裂症和胰岛素抵抗,但需进一步临床验证。
局限性
- 研究所用遗传变异作为暴露代理的基因产物范围未知,无法评论炎症以外的潜在生物学机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Insulin resistance predisposes to cardiometabolic disorders, which are commonly comorbid with schizophrenia and are key contributors to the significant excess mortality in schizophrenia. Mechanisms for the comorbidity remain unclear, but observational studies have implicated inflammation in both schizophrenia and cardiometabolic disorders separately. We aimed to examine whether there is genetic evidence that insulin resistance and 7 related cardiometabolic traits may be causally associated with schizophrenia, and whether evidence supports inflammation as a common mechanism for cardiometabolic disorders and schizophrenia. METHODS AND FINDINGS: We used summary data from genome-wide association studies of mostly European adults from large consortia (Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) featuring up to 108,557 participants; Diabetes Genetics Replication And Meta-analysis (DIAGRAM) featuring up to 435,387 participants; Global Lipids Genetics Consortium (GLGC) featuring up to 173,082 participants; Genetic Investigation of Anthropometric Traits (GIANT) featuring up to 339,224 participants; Psychiatric Genomics Consortium (PGC) featuring up to 105,318 participants; and Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium featuring up to 204,402 participants). We conducted two-sample uni- and multivariable mendelian randomization (MR) analysis to test whether (i) 10 cardiometabolic traits (fasting insulin, high-density lipoprotein and triglycerides representing an insulin resistance phenotype, and 7 related cardiometabolic traits: low-density lipoprotein, fasting plasma glucose, glycated haemoglobin, leptin, body mass index, glucose tolerance, and type 2 diabetes) could be causally associated with schizophrenia; and (ii) inflammation could be a shared mechanism for these phenotypes. We conducted a detailed set of sensitivity analyses to test the assumptions for a valid MR analysis. We did not find statistically significant evidence in support of a causal relationship between cardiometabolic traits and schizophrenia, or vice versa. However, we report that a genetically predicted inflammation-related insulin resistance phenotype (raised fasting insulin (raised fasting insulin (Wald ratio OR = 2.95, 95% C.I, 1.38-6.34, Holm-Bonferroni corrected p-value (p) = 0.035) and lower high-density lipoprotein (Wald ratio OR = 0.55, 95% C.I., 0.36-0.84; p = 0.035)) was associated with schizophrenia. Evidence for these associations attenuated to the null in multivariable MR analyses after adjusting for C-reactive protein, an archetypal inflammatory marker: (fasting insulin Wald ratio OR = 1.02, 95% C.I, 0.37-2.78, p = 0.975), high-density lipoprotein (Wald ratio OR = 1.00, 95% C.I., 0.85-1.16; p = 0.849), suggesting that the associations could be fully explained by inflammation. One potential limitation of the study is that the full range of gene products from the genetic variants we used as proxies for the exposures is unknown, and so we are unable to comment on potential biological mechanisms of association other than inflammation, which may also be relevant. CONCLUSIONS: Our findings support a role for inflammation as a common cause for insulin resistance and schizophrenia, which may at least partly explain why the traits commonly co-occur in clinical practice. Inflammation and immune pathways may represent novel therapeutic targets for the prevention or treatment of schizophrenia and comorbid insulin resistance. Future work is needed to understand how inflammation may contribute to the risk of schizophrenia and insulin resistance.
引用
- Perry BI, Burgess S, Jones HJ, et al. The potential shared role of inflammation in insulin resistance and schizophrenia: A bidirectional two-sample mendelian randomization study. PLoS Med. 2021. PMID: 33711016. doi:10.1371/journal.pmed.1003455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。